Study Finds Low Relapse Risk for Newly Diagnosed MOGAD Patients

A Kaiser Permanente study published in Neurology reports that individuals newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) generally face a low risk of relapse and lasting disability. This finding offers encouraging news for patients managing this rare autoimmune disorder.

Originally published by gnews